August Global Partners

RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. We are committed to fostering diversity at RA, in our portfolio companies, and in the broader biotech community. Who We AreOur flexible strategy allows us to provide seed funding to startups and lead private, IPO, and follow-on financings for our portfolio companies, thereby driving value creation from idea inception through commercialization. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence and, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics. Beyond CapitalRA Capital offers its portfolio companies much more than capital to help them grow, make decisions, and succeed. We:Serve on boards of private and public companies and host board meetings at our offices Help recruit executives and board members Provide access to TechAtlas maps and expertise Prioritize indications and targets based on their feasibility and value given current scientific knowledge, unmet needs, and emerging competition Monitor for new applications and complementary technologies Create custom maps that lay out a company’s competition and unrealized opportunities Provide extra analytical bandwidth across our large team (e.g., analyze literature, provide insights from scientific and investor conferences) Assist with grant writing and preparation of scientific publications Interview clinicians and key opinion leaders (KOLs) Host advisory boards Facilitate partnership or acquisition discussions with larger companies Help design (or redesign) a corporate slide deck or website, leveraging in-house writing and graphics teams Make introductions to other investors Anchor subsequent financings and set the pace for closing Help select bankers for financings and M&A We also provide a growing suite of Innovator Resources to the broader ecosystem, with more hands-on support for our portfolio companies, management teams, and boards. These resources include: a comprehensive reference guide to conducting successful biotech board meetings; a data-driven guide to how to conduct a logical IPO based on first principles of price discovery and shareholder alignment; and a roadmap for how to convey your company’s unique Equity Value Proposition to employees (because they are also your investors). We’re available to coach you through a pitch, provide feedback on a deck, and partner with you to refine strategy or messaging at every stage. Additionally, we helped to found and continue to support No Patient Left Behind, a non-profit dedicated to promoting affordability of today’s medicines and the development of better ones. More specifically, NPLB advocates for insurance reforms that would allow all patients to afford the treatments they need, draws attention to the full societal value of all medicines and the merits of ensuring that all drugs go generic without delay, and educates lawmakers and the public about the workings of the biomedical ecosystem to protect it against misguided policies. Translation & HuntingRA Capital offers Executive-In-Residence (EIR) and venture partner programs for experienced professionals seeking thought partners. We welcome experienced drug hunters searching for technologies/candidates and looking to start new companies to collaborate with our team, explore the capabilities of our in-house incubator, and take advantage of the breadth and depth of our TechAtlas platform. RAVen, our in-house incubator, provides a collaborative platform for drug hunters and company builders to explore both the novel and the re-imagined. Discoveries and improvements in chemistry, molecular and cellular biology, and materials science create novel capabilities that may address unsolved challenges. Our understanding of fundamental biology is constantly evolving, revealing new applications for existing technologies and partially-developed drug candidates. Programs we consider worthwhile may form the basis for a new venture. We believe that when a business proposition is framed correctly, the capital markets have adequate resources and understanding to fund proper experimental design and solution development without forcing companies to cut corners. Furthermore, we have collaborated extensively with other funds that share our philosophy to enable ambitious and capital-intensive endeavors. Our ValuesWe at RA Capital are introspective and deliberate about the ways in which we engage with each other and those outside our firm. Our values represent a set of clear parameters by which we create working relationships founded on trust, collaboration, diligence, and integrity.We originate conviction. We do not borrow it from others. We expect and strive to inspire the best in everyone. We embrace the unfamiliar. We do not let convention stand in the way of what is right. We learn collaboratively. We have a bias for action. We are persistently curious and humbled by what is left to learn. We are data-driven and challenge assumptions. We preserve the ability to change our mind. We admit our mistakes and share lessons learned. We address the elephant in the room. We value our relationships and are positive, respectful, and open-minded. We take fun seriously.

Address the critical bottlenecks in both established and emerging markets that limit access and affordability to novel cancer solutions. Inculcate the tenets of ESG (Environmental, Social and Governance) based investing and measure the progress and impact of our portfolio using the following metrics: E: The ability to optimize differential drug and device pricing based on geography and expand access to promising products early in their lifecycle S: Ability to boost R&D productivity through operational optimization and process transformation G: Promote ethical conduct of business and collaboration while ensuring inclusion & diversity What We DoInvest in US and EU based cancer start-ups who are keen to explore emerging markets or engage in collaborative R&D. Streamline the product-market fit and ensure access to supportive infrastructure and resources. Facilitate their collaborative R&D/commercialization strategy in geographies of interest. How We Do It Accelerate the path to successful commercialization for US and EU based start-ups developing the next generation of oncology solutions by: Reducing costs through infrastructure consolidation and collaborative expertise Expanded access to capital Facilitating rapid market penetration and commercial scaling​

Cathay Health is dedicated to investing in companies at the convergence of life sciences, healthcare and technology with positive impact on human health. With a reach spanning key bio and tech hubs around the globe, we help companies scale across borders and access new markets, partners and patients. Our Strategy We back venture- and growth-stage companies with emerging technologies that catalyze groundbreaking advances in healthcare. We fund future leaders in tech-enabled medicine with differentiated approaches and strong intellectual property to personalize care, improve access and lower cost. We invest in Series A to C rounds with the ability to lead or co-invest, and help companies scale across borders. Our Focus AreasLife Science Tools Diagnostics Clinical Trial Innovation New Care Models Novel Devices & Materials Enabling Technologies For Advanced Therapies Why Cathay HealthA global platform catalyzing cross-industry collaboration: Cathay Health is affiliated to Cathay Capital – a global investment platform connecting partners and catalyzing collaborations across Europe, North America and Asia to solve the world’s most pressing challenges. Scaling companies to transform health across borders: Our global network and operating expertise across regions allows us to grow impactful companies that serve patients worldwide. Deep expertise in both healthcare and technology: Our unique expertise allows us to identify investment opportunities with the largest impact on human health and care. Investing & operating at the convergence Our team not only invests – but brings operating experience – at the convergence of life sciences, healthcare and tech. Our expertise uniquely bridges these complementary fields to maximize the potential of our portfolio companies.

Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide. Investing in early-stage venture capital We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. Leveraging a competitive advantage Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. #1 in hospital medical research​ Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce. Legacy of investing in medical innovation Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham. Editas Medicine: IPO Feb. 2016 (NASDAQ: EDIT) Unlocking the power and potential of CRISPR genome editing technology. CoStim Pharmaceuticals: Acquired by Novartis, Feb. 2014 Next-generation immuno-oncology drugs based on T-cell costimulatory targets. Keros Therapeutics: IPO April 2020 (NASDAQ: KROS) Novel treatments for patients suffering from hematologic and musculoskeletal disorders. Our investment strategy We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies. Leveraging a proven approach:The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies. We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients Competitive advantage of Mass General Brigham: The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors. Academic medical centers: We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.

Intuitive Ventures invests in and accelerates the digital, therapeutic, diagnostic, and device ecosystems of minimally invasive care. Our unique access to Intuitive’s industry-leading knowledge, care delivery innovation, and commercial reach, empowers us to cultivate the potential of startups that are advancing positive outcomes in healthcare. Through our inaugural $100 million fund, Intuitive Ventures is focused on accelerating the future of minimally invasive care by moving the ecosystem forward. What we do Intuitive Ventures extends Intuitive's commitment to converging robotic systems, digital tools, and clinical need in search of new ways to understand, diagnose, treat, and manage disease. We apply Intuitive’s strengths and abilities in the fields of robotic surgery and minimally invasive care to support independent initiatives in four focus areas: Digital – transformative business models and solutions improving outcomes across the patient care continuum Therapeutics – precision focal therapeutics and biotech innovations delivered to the right patient at the right place and the right time Diagnostics – powering earlier disease detection and therapeutic activation across clinical pathways Devices – novel and digitally-native medical device platforms pushing the boundaries of patient care What sets us apart: Aligned for success – our nimble structure and financial alignment empower us to invest early and to support our portfolio companies pioneer markets Wealth of experience – we provide the resources and guidance needed to support our entrepreneurs and management teams reach their major milestones Deep strategic value – we leverage the unique strengths of Intuitive to accelerate the impact of our portfolio companies

Wellington Partners is a leading European venture capital firm supporting outstanding entrepreneurs and their products on their way to market leadership. We have already invested in more than 50 early- and growth-stage life science companies, active in the fields of biotechnology, therapeutics, medical devices, diagnostics and digital health. We do not only provide financial resources, but also contribute our expertise, hard work and passion to help world class teams in building successful businesses of exceptional growth. Working hand in hand with our portfolio companies, we turn big ideas into big successes. We provide world class entrepreneurs with the capital for the financing of breakthrough products with the potential to decisively improve current standard of care and, most importantly, the lives of patients. We proactively source deals and lead or co-lead financing rounds, from early stage to expansion stage and selected PIPE investments (Private Investment in Public Equity). Our ticket sizes typically range from EUR 2 million to EUR 20 million. All-round support for all stages of growth Providing funding is only one part of our business, with long-term commitment and active collaboration being the other. Our team consists of both MDs and PhDs and brings together a unique combination of passionate and committed people, extensive investment experience and company-building skills. Our role is to offer board level strategic support to entrepreneurs while they exercise operational control. Together with our global scientific and commercial network, we are in a position to organize financing rounds, accelerate preclinical and clinical development, regulatory approval processes, and drive successful market entry into the most important healthcare markets in Europe, the U.S. and Asia. Successful exits We know that success does not happen overnight and we are prepared to accompany entrepreneurs for as long as it might take to transform great ideas into great successes and ultimately deliver outstanding results for those we serve – patients, entrepreneurs, and the people and organizations that entrust us with their capital. More than 20 of our portfolio companies have already achieved a successful exit or IPO. Here are a few examples: Definiens Rigontec Themis Bioscience Invendo medical Sapiens Atopix Therapeutics Oxford Immunotec MTM Laboratories